Keyphrases
Acute Myeloid Leukemia
96%
Venetoclax
45%
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
45%
Newly Diagnosed
40%
Chronic Myeloid Leukemia
35%
Phase II Study
29%
Myelofibrosis
26%
Complete Remission
26%
Relapsed or Refractory
25%
Relapsed or Refractory Acute Myeloid Leukemia
24%
Overall Survival
24%
Hypomethylating Agents
22%
Tagraxofusp
22%
Myelodysplastic Syndrome
22%
CD123
22%
Myeloproliferative Neoplasms
21%
Ruxolitinib
20%
Phase II Trial
16%
Intensive Chemotherapy
15%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
15%
Decitabine
15%
Azacitidine
14%
Median Overall Survival
14%
Older Patients
14%
Targeted Therapy
13%
Cytarabine
13%
FMS-like Tyrosine Kinase 3 (FLT3)
11%
Polycythemia Vera
11%
Tyrosine Kinase Inhibitor
11%
Hematological Malignancies
10%
Single Center
10%
Frontline Therapy
10%
High Risk
10%
Leukemia
9%
Dasatinib
9%
Monotherapy
9%
Cyclophosphamide
8%
Event-free Survival
8%
Cladribine
8%
Clinical Outcomes
8%
Idarubicin
8%
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
8%
Older Adults
8%
Complete Response
8%
Clinical Trials
8%
Ponatinib
8%
Bone Marrow
8%
Leukemia Patients
8%
Chemotherapy
8%
High-risk Myelodysplastic Syndrome
8%
Medicine and Dentistry
Acute Myeloid Leukemia
87%
Neoplasm
52%
Plasmacytoid Dendritic Cell
42%
Venetoclax
41%
Overall Survival
34%
Diseases
30%
Myeloproliferative Neoplasm
29%
Myelofibrosis
28%
Myelodysplastic Syndrome
22%
Hypomethylating Agent
21%
Clinical Trial
16%
Tagraxofusp
16%
Ruxolitinib
15%
Acute Lymphoblastic Leukemia
13%
Chronic Myelogenous Leukemia
13%
Azacitidine
13%
Philadelphia 1 Chromosome
13%
Targeted Therapy
12%
Polycythemia vera
12%
Tyrosine-Kinase Inhibitor
12%
Chronic Myelomonocytic Leukemia
12%
Acute Myelogenous Leukemia
11%
Cancer
11%
Arm
11%
Decitabine
11%
Leukemia
10%
Cytarabine
10%
Oncology
10%
Adverse Event
10%
Janus Kinase Inhibitor
10%
Minimal Residual Disease
9%
Malignant Neoplasm
9%
Hematologic Malignancy
9%
Adolescence
8%
Event Free Survival
8%
Hematology
8%
Monotherapy
7%
Vincristine
7%
Ponatinib
7%
Myeloid Malignancy
7%
Myeloid Leukemia
7%
Dexamethasone
6%
Cyclophosphamide
6%
Low Drug Dose
6%
Doxorubicin
6%
Pediatrics
6%
Cladribine
5%
Acute Promyelocytic Leukemia
5%
B-Cell Chronic Lymphocytic Leukemia
5%
Janus Kinase
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Venetoclax
43%
Neoplasm
42%
Overall Survival
39%
Remission
33%
Chemotherapy
32%
Myelofibrosis
29%
Myelodysplastic Syndrome
27%
Diseases
23%
Cytarabine
22%
Tagraxofusp
21%
Ruxolitinib
20%
Azacitidine
19%
Clinical Trial
19%
Acute Lymphoblastic Leukemia
18%
Decitabine
16%
Myeloproliferative Neoplasm
16%
Chronic Myeloid Leukemia
15%
Adverse Event
14%
Polycythemia vera
13%
Philadelphia 1 Chromosome
12%
Protein Tyrosine Kinase Inhibitor
12%
Chronic Myelomonocytic Leukemia
11%
Leukemia
11%
Minimal Residual Disease
10%
Idarubicin
9%
Malignant Neoplasm
9%
Monotherapy
8%
Event Free Survival
8%
Vincristine
8%
Secondary Acute Myeloid Leukemia
8%
Myeloid Leukemia
8%
Janus Kinase Inhibitor
8%
Dexamethasone
8%
Cyclophosphamide
8%
Cladribine
7%
Hematologic Malignancy
7%
Dasatinib
7%
Fludarabine
6%
Ponatinib
6%
Doxorubicin
6%
Clofarabine
5%
Inotuzumab Ozogamicin
5%
Core Binding Factor
5%